A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.
作者信息
Varkaris Andreas, Stevens Julia, Ono Yuho, Balk Steven P, Bellmunt Joaquim
机构信息
Division of Hematology-Oncology, Department of Medicine, and Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School. Boston, MA.
出版信息
JCO Precis Oncol. 2022 Feb;6:e2100091. doi: 10.1200/PO.21.00091.
Abstract
摘要
相似文献
1
A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.一例醋酸阿比特龙治疗后出现雄激素受体T878A孕酮反应性突变的前列腺癌病例，对达洛鲁胺有反应。
JCO Precis Oncol. 2022 Feb;6:e2100091. doi: 10.1200/PO.21.00091.
2
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).迈向精准泌尿肿瘤学：利用新型抑制剂达罗他胺（ODM-201）靶向恩杂鲁胺耐药前列腺癌和雄激素受体突变体。
Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26.
3
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.阿比特龙治疗去势抵抗性前列腺癌会筛选出对孕酮有反应的突变雄激素受体。
Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.
4
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines.醋酸阿比特龙在人前列腺癌细胞系中发挥细胞毒性作用。
Naunyn Schmiedebergs Arch Pharmacol. 2019 Jun;392(6):729-742. doi: 10.1007/s00210-019-01622-5. Epub 2019 Feb 15.
5
Abiraterone acetate in the treatment of prostate cancer.醋酸阿比特龙治疗前列腺癌。
Biomed Pharmacother. 2018 May;101:211-218. doi: 10.1016/j.biopha.2018.02.067. Epub 2018 Feb 26.
6
Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.血液中AR-V7与前列腺特异性抗原RNA水平与醋酸阿比特龙和恩杂鲁胺治疗前列腺癌男性疗效的关联
Clin Cancer Res. 2017 Feb 1;23(3):726-734. doi: 10.1158/1078-0432.CCR-16-1070. Epub 2016 Aug 3.
7
Steroid sidestep: evading androgen ablation by abiraterone.类固醇规避：阿比特龙规避雄激素剥夺
Clin Cancer Res. 2015 Mar 15;21(6):1240-2. doi: 10.1158/1078-0432.CCR-14-2899. Epub 2014 Nov 28.
8
Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.达洛鲁胺作为第二代雄激素受体抑制剂在前列腺癌治疗中的应用
Curr Mol Med. 2021;21(4):332-346. doi: 10.2174/1566524020666200903120344.
9
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.阿比特龙耐药性前列腺癌的旁路机制：积累的 CYP17A1 底物激活雄激素受体信号。
Prostate. 2019 Jun;79(9):937-948. doi: 10.1002/pros.23799. Epub 2019 Apr 24.
10
Recent Advances in Prostate Cancer Treatment and Drug Discovery.前列腺癌治疗与药物研发的最新进展。
Int J Mol Sci. 2018 May 4;19(5):1359. doi: 10.3390/ijms19051359.
引用本文的文献
1
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer.核因子I介导的染色质可及性增加驱动前列腺癌向雄激素受体剪接变体依赖性转变。
Cell Rep. 2025 Jan 28;44(1):115089. doi: 10.1016/j.celrep.2024.115089. Epub 2024 Dec 21.
2
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌中雄激素受体信号抑制剂耐药的基因组和转录组特征。
J Clin Invest. 2024 Aug 13;134(19):e178604. doi: 10.1172/JCI178604.
本文引用的文献
1
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.多中心二期临床试验研究恩杂鲁胺在转移性去势抵抗性前列腺癌中识别耐药机制
Clin Cancer Res. 2021 Jul 1;27(13):3610-3619. doi: 10.1158/1078-0432.CCR-20-4616. Epub 2021 Apr 13.
2
Genomic correlates of clinical outcome in advanced prostate cancer.晚期前列腺癌的临床结局的基因组相关性。
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.
3
Plasma AR and abiraterone-resistant prostate cancer.血浆雄激素受体与阿比特龙耐药性前列腺癌
Sci Transl Med. 2015 Nov 4;7(312):312re10. doi: 10.1126/scitranslmed.aac9511.
4
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.阿比特龙治疗去势抵抗性前列腺癌会筛选出对孕酮有反应的突变雄激素受体。
Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.
5
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.醋酸阿比特龙联合醋酸亮丙瑞林对局限性高危前列腺癌患者进行强化雄激素剥夺治疗：一项随机II期新辅助研究的结果
J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.
6
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.转移性雄激素非依赖型前列腺癌中雄激素受体基因的突变
N Engl J Med. 1995 May 25;332(21):1393-8. doi: 10.1056/NEJM199505253322101.
Zotero 插件